Cover Image

Daidzein plus isolase associated with zinc improves clinical symptoms and quality of life in patients with LUTS due to benign prostatic hyperplasia: Results from a phase I-II study

Daniele Tiscione, Luca Gallelli, Irene Tamanini, Lorenzo Giuseppe Luciani, Paolo Verze, Alessandro Palmieri, Vincenzo Mirone, Riccardo Bartoletti, Gianni Malossini, Tommaso Cai
  • Daniele Tiscione
    Department of Urology, Santa Chiara Regional Hospital, Trento, Italy
  • Luca Gallelli
    Department of Health Science, School of Medicine, University of Catanzaro, Catanzaro, Italy
  • Irene Tamanini
    Department of Urology, Santa Chiara Regional Hospital, Trento, Italy
  • Lorenzo Giuseppe Luciani
    Department of Urology, Santa Chiara Regional Hospital, Trento, Italy
  • Paolo Verze
    Department of Urology, University of Naples, Federico II, Naples, Italy
  • Alessandro Palmieri
    Department of Urology, University of Naples, Federico II, Naples, Italy
  • Vincenzo Mirone
    Department of Urology, University of Naples, Federico II, Naples, Italy
  • Riccardo Bartoletti
    Department of Urology, University of Pisa, Pisa, Italy
  • Gianni Malossini
    Department of Urology, Santa Chiara Regional Hospital, Trento, Italy

Abstract

Objective: In the last years there is a growing interest in nutraceutical substances that seems able to improve clinical symptoms in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). In this paper, we evaluated both efficacy and safety of a combination of daidzein with isolase and zinc in patients with LUTS due to BPH. Materials and methods: In a phase I-II study clinical trial we enrolled patients with clinical and instrumental diagnosis of LUTS associated to BPH that received a six-month treatment with a combination of daidzein with isolase and zinc (1 tablet/day). Clinical, laboratory and instrumental analyses were carried out at the time of admission (T0) and 6 months after the ending of the treatment (T1). The Italian version of International Prostatic Symptom Score (IPSS), International Index of Erectile Function (IIEF-5) and Quality of Well-Being (QoL) questionnaires were used. The development of adverse drug reactions (ADRs) and drug interactions (DDIs) were recorded using the Naranjo scale and drug interaction probability scale. Student’s t test and Anova test were used for statistical analysis, and the threshold of statistical significance was set at P < 0.05. Results: We enrolled 71 patients, 62 (87.3%) completed the follow-up and we documented a significant differences between T0 and T1 in terms of IPSS [21.5 ± 1.2 vs 16.2 ± 1.5; (-4.8); p < 0.001], Cmax [9.7 ± 3.7 vs 15.3 ± 2.5; (+5.6); p < 0.001] and QoL [0.56 ± 0.15 vs 0.84 ± 0.19; (+0.28); p < 0.001]. In contrast, no significant difference were recorded in terms of IIEF-5 [p = 0.50] and PSA [p = 0.67]. Finally, we did not record any significant ADRs or DDIs during the study. Conclusions: In this study, we documented that a combination of daidzein with isolase and zinc, reduces the clinical symptoms of LUTS and improves the quality of life in patients with BPH, without the development of ADRs or DDIs.

Keywords

BPH; Zinc; LUTS; Equol; Isoflavones; Medical treatment

Full Text:

PDF
Submitted: 2017-01-20 18:10:51
Published: 2017-03-31 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
166

Views:
PDF
124

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2017 Daniele Tiscione, Luca Gallelli, Irene Tamanini, Lorenzo G Luciani, Paolo Verze, Alessandro Palmieri, Vincenzo Mirone, Riccardo Bartoletti, Gianni Malossini, Tommaso Cai

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185